Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.58 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.58 |
| ▸ | IGF2R | P11717 | 2/20 | 0.52 |
| ▸ | MDK | P21741 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.48 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | BDNF | P23560 | 2/20 | 0.46 |
| ▸ | PTN | P21246 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16063765 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4IGF2RMDK | |
| SCHEMBL18494404 | 0.94 | LGALS3 (0.56) | LGALS8LGALS3LGALS4IGF2RMDK | |
| SCHEMBL16063647 | 0.94 | LGALS3 (0.53) | LGALS8LGALS3LGALS4IGF2RMDK | |
| SCHEMBL18494820 | 0.94 | LGALS3 (0.53) | LGALS8LGALS3LGALS4IGF2RMDK | |
| SCHEMBL18494405 | 0.94 | LGALS3 (0.53) | LGALS8LGALS3LGALS4IGF2RMDK | |
| SCHEMBL19726142 | 0.88 | LGALS3 (0.73) | LGALS8LGALS3LGALS4IGF2RMAPK1 | |
| SCHEMBL16996680 | 0.88 | LGALS3 (0.58) | LGALS8LGALS3LGALS4IGF2RMDK | |
| SCHEMBL27433373 | 0.88 | LGALS3 (0.56) | LGALS8LGALS3LGALS4MDKMAPK1 | |
| SCHEMBL21321488 | 0.87 | IGF2R (0.65) | LGALS8LGALS3LGALS4IGF2RHPSE | |
| SCHEMBL21233299 | 0.87 | IGF2R (0.65) | LGALS8LGALS3LGALS4IGF2RHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180142227-A1 | COAGULATION FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180142227-A1 | COAGULATION FACTOR VII POLYPEPTIDES | F7, F13B, HABP2 | LGALS8 1604/4885LGALS3 2458/4885LGALS4 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.